Nuwellis price target lowered to $13 from $16 at Roth MKM

Roth MKM analyst Jonathan Aschoff lowered the firm’s price target on Nuwellis (NUWE) to $13 from $16 and keeps a Buy rating on the shares following the Q4 report. The company’s cash of $5.1M should fund operations into Q2 of 2025, the analyst tells investors in a research note. The firm believes the four-times increase in Aquadex reimbursement, that started in early Q1, should support future revenue growth.